Skip to main content

Advertisement

Log in

The use of mirabegron in neurogenic bladder: a systematic review

  • Invited Review
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the use of mirabegron in patients with neurogenic bladder.

Methods

A systematic review of the literature was conducted using four databases (Medline via PubMed, Scopus, Cochrane, and EMBASE). Articles evaluating mirabegron in neurogenic bladder patients were collected, and assessment of the drug’s efficacy was reviewed according to clinical and urodynamic parameters.

Results

Seven studies were selected and a total of 302 patients with NB were evaluated, ranging from 15 to 66 patients per study. All of the patients had received antimuscarinics as a previous treatment modality. Mirabegron was used as a second-line treatment after antimuscarinics lacked efficacy or caused adverse effects. The duration of the treatments ranged from 4 to 12 weeks. Reported in two studies each, bladder compliance and maximal cystometric capacity were the most commonly improved urodynamic parameters. In the majority of the studies, positive outcomes were reported for clinical scores. Additionally, analysis of the IPSS subscores revealed an improvement of storage symptoms as opposed to voiding symptoms. In all of the studies, mirabegron was well tolerated.

Conclusion

Mirabegron appears to be an effective treatment in the management of neurogenic bladder unresponsive to antimuscarinics, particularly in patients presenting with storage symptoms. There is still no evidence concerning the use of mirabegron as a first-line therapy for neurogenic bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Manack A, Motsko SP, Haag-Molkenteller C et al (2013) Epidemiology and Healthcare Utilization of Neurogenic Bladder Patients in a US Claims Database. Neurourol Urodyn 32:215–223. https://doi.org/10.1002/nau

    Article  Google Scholar 

  2. Oh SJ, Shin HI, Paik NJ et al (2006) Depressive symptoms of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Spinal Cord 44:757–762. https://doi.org/10.1038/sj.sc.3101903

    Article  PubMed  Google Scholar 

  3. Oh SJ, Ku JH, Jeon HG et al (2004) Health-related quality of life of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Urology. https://doi.org/10.1016/j.urology.2004.09.032

    Article  PubMed  Google Scholar 

  4. Lawerson A, Wyndaele JJ, Vlachonikolis I et al (2001) Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology 20:138–143

    Article  Google Scholar 

  5. Ginsberg D (2013) The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care 19:191–196

    Google Scholar 

  6. Cameron AP (2010) Pharmacologic therapy for the neurogenic bladder. Urol Clin NA 37:495–506. https://doi.org/10.1016/j.ucl.2010.06.004

    Article  Google Scholar 

  7. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 62:816–830. https://doi.org/10.1016/j.eururo.2012.02.036

    Article  CAS  PubMed  Google Scholar 

  8. Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF (2017) Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr 69:77–96. https://doi.org/10.1016/j.archger.2016.11.006

    Article  CAS  PubMed  Google Scholar 

  9. Kim A, Lee KS, Jung R et al (2017) Health related quality of life in patients with side-effects after antimuscarinic treatment for overactive bladder. LUTS Low Urin Tract Symptoms 9:171–175. https://doi.org/10.1111/luts.12132

    Article  CAS  PubMed  Google Scholar 

  10. Engeler DS, Meyer D, Abt D et al (2015) Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol 15:4–9. https://doi.org/10.1186/s12894-015-0102-x

    Article  Google Scholar 

  11. Herschorn S, Gajewski J, Ethans K et al (2011) Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a Randomized, double-blind trial. J Urol 185:2229–2235. https://doi.org/10.1016/j.juro.2011.02.004

    Article  CAS  PubMed  Google Scholar 

  12. Korstanje C, Suzuki M, Yuno K et al (2017) Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron. J Pharmacol Toxicol Methods 87:74–81. https://doi.org/10.1016/j.vascn.2017.04.008

    Article  CAS  PubMed  Google Scholar 

  13. Rosa GM, Baccino D, Valbusa A et al (2018) Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. Expert Opin Drug Saf 17:487–497. https://doi.org/10.1080/14740338.2018.1453496

    Article  CAS  PubMed  Google Scholar 

  14. Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. https://doi.org/10.1186/2046-4053-4-1

    Article  PubMed  PubMed Central  Google Scholar 

  15. Park JS, Lee YS, Lee CN et al (2018) Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. https://doi.org/10.1007/s00345-018-2576-0

    Article  PubMed  Google Scholar 

  16. Zachariou A, Filiponi M, Baltogiannis D et al (2017) Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol 24:9107–9113

    PubMed  Google Scholar 

  17. Welk B, Hickling D, McKibbon M et al (2018) A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn 37:2810–2817. https://doi.org/10.1002/nau.23774

    Article  CAS  PubMed  Google Scholar 

  18. Wöllner J, Pannek J (2016) Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 54:78–82. https://doi.org/10.1038/sc.2015.195

    Article  PubMed  Google Scholar 

  19. Krhut J, Borovička V, Bílková K et al (2018) Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 37:2226–2233. https://doi.org/10.1002/nau.23566

    Article  CAS  PubMed  Google Scholar 

  20. Chen SF, Kuo HC (2019) Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. LUTS Low Urin Tract Symptoms 11:O53–O58. https://doi.org/10.1111/luts.12215

    Article  CAS  PubMed  Google Scholar 

  21. Matsuo T, Miyata Y, Nakamura T et al (2019) Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. LUTS Low Urin Tract Symptoms 11:O65–O70. https://doi.org/10.1111/luts.12218

    Article  CAS  PubMed  Google Scholar 

  22. Robinson D, Thiagamoorthy G, Cardozo L (2016) A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin Drug Saf 15:689–696. https://doi.org/10.1517/14740338.2016.1165663

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

EEH: project development, data collection, data analysis, and manuscript writing. CL: data collection, data analysis, and manuscript writing. RC: data collection, data analysis, and manuscript writing. JEH: project development, data collection, and manuscript writing. GAT: data analysis and manuscript editing. GJ: data analysis and manuscript editing. EN: project development and manuscript writing.

Corresponding author

Correspondence to Elie El Helou.

Ethics declarations

Conflict of interest

The authors have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Helou, E., Labaki, C., Chebel, R. et al. The use of mirabegron in neurogenic bladder: a systematic review. World J Urol 38, 2435–2442 (2020). https://doi.org/10.1007/s00345-019-03040-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-019-03040-x

Keywords

Navigation